Dakota Wealth Management Has $1.06 Million Stock Holdings in Tempus AI, Inc. $TEM

Dakota Wealth Management lessened its position in Tempus AI, Inc. (NASDAQ:TEM) by 75.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,184 shares of the company’s stock after selling 41,388 shares during the quarter. Dakota Wealth Management’s holdings in Tempus AI were worth $1,064,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in TEM. Royal Bank of Canada grew its position in Tempus AI by 201.2% in the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after acquiring an additional 17,359 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Tempus AI in the first quarter worth $116,000. State of New Jersey Common Pension Fund D acquired a new stake in Tempus AI in the 2nd quarter worth $2,020,000. Envestnet Asset Management Inc. increased its position in shares of Tempus AI by 2.6% during the second quarter. Envestnet Asset Management Inc. now owns 62,005 shares of the company’s stock valued at $3,940,000 after purchasing an additional 1,558 shares during the period. Finally, Amalgamated Bank acquired a new position in Tempus AI in the second quarter worth about $394,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Price Performance

Tempus AI stock opened at $55.41 on Friday. Tempus AI, Inc. has a one year low of $36.22 and a one year high of $104.32. The stock’s fifty day moving average price is $61.57 and its two-hundred day moving average price is $73.33. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.12. The firm has a market cap of $9.86 billion, a PE ratio of -39.30 and a beta of 5.22.

Insider Transactions at Tempus AI

In related news, CFO James William Rogers sold 10,084 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $595,460.20. Following the sale, the chief financial officer owned 101,166 shares of the company’s stock, valued at $5,973,852.30. This trade represents a 9.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Andrew Polovin sold 10,949 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the transaction, the executive vice president owned 126,918 shares of the company’s stock, valued at $7,654,424.58. This represents a 7.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 596,035 shares of company stock valued at $37,505,125. Corporate insiders own 26.27% of the company’s stock.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q4 beat with strong top-line growth and raised 2026 revenue guidance — Tempus reported robust revenue growth (driven by diagnostics, MRD and Data & Applications), narrowed losses and issued a 2026 revenue target of about $1.59B, supporting the company’s growth-and-path-to-profit narrative. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Positive Sentiment: New AI tools and a strategic partnership broaden addressable market — Tempus launched an HRD‑RNA AI algorithm for oncology and partnered with Median Technologies to integrate advanced lung‑cancer screening tools, strengthening its diagnostic pipeline and platform differentiation. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Neutral Sentiment: CEO to speak at Morgan Stanley TMT conference — Eric Lefkofsky will appear March 3; the presentation is a near-term opportunity to clarify guidance, margin cadence and commercialization progress. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Analyst coverage and comparisons continue to shape expectations — industry writeups (e.g., TEM vs. ILMN) emphasize the balance between near‑term execution and long‑term transformation in medtech/AI healthcare, making investor focus on execution more acute. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
• Negative Sentiment: Multiple price‑target cuts this week pressured sentiment — JPMorgan cut its target to $60 (neutral), Needham lowered to $75 (buy), and BTIG trimmed to $90 — that combination tightened near-term upside expectations despite mixed analyst ratings. JPMorgan price target cut Needham price target lowered BTIG price target cut
• Negative Sentiment: After‑hours reaction driven by wider loss and profitability concerns — despite revenue outperformance, EPS missed and some commentary left investors unsure about near‑term margin/scale progress, prompting a pullback in the session following the print. TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TEM shares. Canaccord Genuity Group cut their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. BTIG Research cut their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday. Needham & Company LLC reduced their price objective on shares of Tempus AI from $100.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, HC Wainwright decreased their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $79.31.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.